Marcelo Lima

Mr. Marcelo Lima

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RFRenata De Carvalho Feitosa
Renata De Carvalho Feitosa
Juliana Souza Ribeiro CostaJuliana Souza Ribeiro Costa
Juliana Souza Ribeiro Costa
MLMarcelo Lima
Marcelo Lima
EIElina Sawa Akioka Ishikawa
Elina Sawa Akioka Ishikawa
KMKarina Cogo Müller
Karina Cogo Müller
LOLaura Oliveira-Nascimento
Laura Oliveira-Nascimento
Doxycycline (DX) is a well-established and broad-spectrum antimicrobial drug. However, DX has drawbacks, such as physicochemical instability in aqueous media and bacterial resistance. The inclusion of drugs in cyclodextrin complexes and their loading into nanocarriers can overcome these limitations. Thus, we studied the DX/sulfobutylether-β-CD (SBE-β-CD) inclusion complex for the first time and used it to reticulate chitosan. The resulting particles were evaluated by their physicochemical characteristics and antibacterial activity. DX/SBE-β-CD complexes were characterized by nuclear magnetic resonance, infrared spectroscopy, thermal analysis, X-ray diffraction, and scanning electron microscopy (SEM), whereas DX-loaded nanoparticles were characterized by dynamic light scattering, SEM, and drug content. The partial inclusion of the DX molecule in CD happened in a 1:1 proportion and brought increased stability to solid DX upon thermal degradation. Chitosan-complex nanoparticles measured approximately 200 nm, with a narrow polydispersity and particles with sufficient drug encapsulation for microbiological studies. Both formulations preserved the antimicrobial activity of DX against Staphylococcus aureus, whereas DX/SBE-β-CD inclusion complexes were also active against Klebsiella pneumoniae, indicating the potential use of these formulations as drug delivery systems to treat local infections.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
RFRenata De Carvalho Feitosa
Renata De Carvalho Feitosa
Juliana Souza Ribeiro CostaJuliana Souza Ribeiro Costa
Juliana Souza Ribeiro Costa
MLMarcelo Lima
Marcelo Lima
EIElina Sawa Akioka Ishikawa
Elina Sawa Akioka Ishikawa
KMKarina Cogo Müller
Karina Cogo Müller
LOLaura Oliveira-Nascimento
Laura Oliveira-Nascimento
Doxycycline (DX) is a well-established and broad-spectrum antimicrobial drug. However, DX has drawbacks, such as physicochemical instability in aqueous media and bacterial resistance. It is known that the inclusion of drugs in cyclodextrin complexes and their loading in nanocarriers can overcome these limitations. Thus, we developed DX/sulfobutylether-β-CD (SBE-β-CD) inclusion complexes and DX-loaded nanoparticles, evaluating their physicochemical characteristics and antibacterial activity. DX/SBE-β-CD complexes were characterized by nuclear magnetic resonance, infrared spectroscopy, thermal analysis, X-ray diffraction and scanning electron microscopy (SEM), whereas DX-loaded nanoparticles were characterized by dynamic light scattering, SEM and drug content. Complexes and chitosan nanoparticles presented approximately 200 nm size, narrow polydispersity and particles with sufficient drug encapsulation (25%) for microbiological studies. Both formulations showed antimicrobial activity against Staphylococcus aureus, whereas DX/SBE-β-CD inclusion complexes were also active against Klebsiella pneumoniae , indicating the potential use of these formulations as drug delivery systems to treat local infections.